Abstract
Background. For more than 3000 years, medical conditions known as hypertensive states of pregnancy have been described. Hippocrates described epileptic seizures, while in the first century Celsus linked epileptic seizures to fetal death. Galen distinguished between epilepsy and peripheral epilepsy. Maternal mortality due to epilepsy reaches 44% and perinatal mortality reaches 27.8%. Homocysteine is related to PE between 20 and 30%, and an increase in PE or hyperhomocysteine may be the result of a genetic defect in the enzyme methylenetetrahydrofolate reductase (MTFHR) that is involved in homocysteine synthesis. The purpose of this study was to identify homocysteine levels in pregnant women between 16 and 20 weeks as an indicator of the likelihood of developing preeclampsia. Material and method. - It was an observational, longitudinal and prospective research. The study population consisted of patients who attended the first prenatal care consultation between 16 and 20. weeks, the sample was randomized that included 312 patients who were determined to have serum homocysteine. Results. 270 patients (86.5% of the total) had a normal pregnancy. 27 patients (8.65%) developed gestational hypertension, 9 (2.88%) had mild PE, and 6 (1.9%) had none developed HELLP syndrome. Homocysteine levels in patients with preeclampsia were in the standard range (11.05). Conclusions. In the current analysis, the frequency of hypertensive disease in pregnancy was found to be 13.5%. There is no correlation found between homocysteine levels and the development of hypertensive disease during pregnancy.
DOI:https://doi.org/10.56238/sevened2024.031-023